(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 July 2010 (01.07.2010)

PCT

(10) International Publication Number
WO 2010/075074 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) *A61P 35/00* (2006.01)
A61K 31/517 (2006.01)

(21) International Application Number:
PCT/US2009/068030

(22) International Filing Date:
15 December 2009 (15.12.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
08380343.7 22 December 2008 (22.12.2008) EP
61/154,954 24 February 2009 (24.02.2009) US

(71) Applicant *(for all designated States except US)*: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **COATES, David, Andrew** [US/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **DE DIOS MAGANA, Alfonso** [ES/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **DE PRADO GONZALES, Ana** [ES/ES]; Lilly S.A., Avenida de la Industria 30, E-28108 Alcobendas, Madrid (ES). **DEL PRADO CATALINA, Miriam Filadelfa** [ES/ES]; Lilly S.A., Avenida de la Industria 30, E-28108 Alcobendas, Madrid (ES). **GARCIA PAREDES, Maria, Cristina** [ES/ES]; Lilly S.A., Avenida de la Industria 30, E-28108 Alcobendas, Madrid (ES). **GELBERT, Lawrence, Mark** [US/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **KNOBELOCH, John, Monte** [US/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **MARTIN DE LA NAVA, Eva, Maria** [ES/ES]; Lilly S.A., Avenida de la Industria 30, E-28108 Alcobendas, Madrid (ES). **MARTIN ORTEGA FINGER, Maria, Dolores** [ES/ES]; Lilly S.A., Avenida de la Industria 30, E-28108 Alcobendas, Madrid (ES). **MARTINEZ PEREZ, Jose, Antonio** [ES/ES]; Lilly S.A., Avenida de la Industria 30, E-28108 Alcobendas, Madrid (ES). **MATEO HERRANZ, Ana, Isabel** [ES/ES]; Lilly S.A., Avenida de la Industria 30, E-28108 Alcobendas, Madrid (ES). **PEREZ MARTINEZ, Carlos** [ES/ES]; Lilly S.A., Avenida de la Industria 30, E-28108 Alcobendas, Madrid (ES). **SANCHEZ MARTINEZ, Concepcion** [ES/ES]; Lilly S.A., Avenida de la Industria 30, E-28108 Alcobendas, Madrid (ES).

(74) Agents: **HOSTETTLER, Danica** et al.; Eli Lilly And Company, Patent Division, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM,

[Continued on next page]

(54) Title: PROTEIN KINASE INHIBITORS



(I)

(57) Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.

WO 2010/075074 A1

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*